BioWorld

March 25, 2008

Zogenix Eyes Public Markets, Files for Potential $86M IPO

Only days after the FDA accepted for review Zogenix Inc.'s new drug application for its needle-free sumatriptan candidate, the San Diego-based firm filed for an initial public offering. (BioWorld Today) Read More

Cytokinetics Sees Shares Rise on Positive Heart Drug Data

Parkinson's Treated with SCNT as Genomics Data Find Home

NewCo News: Influmedix Plans to Go Multiple Rounds With M Channel Target

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...